Doer Biotech Selected for Hangzhou's 2024 High-Quality Biopharmaceutical Development Special Funding Program
Doer Biologics
Biological Drug Developer
On December 5, 2024, the Hangzhou Science and Technology Bureau announced the "List of Proposed Subsidy Projects for Specific Categories of the 2024 High-Quality Development Special Fund for Hangzhou's Biomedical Industry," and Doer Biologics successfully made it onto the list.
Doer Biologics' "Research and Development of Class I Innovative Biologic DR10624" project has been successfully selected for the "Support for Preclinical Drug Research" subsidy program list.First of all, we would like to express our gratitude to the Hangzhou Science and Technology Bureau for their recognition and support. Receiving funding from the Hangzhou Science and Technology Bureau is not only an affirmation of Doer Biologics' relentless pursuit of innovation in the biopharmaceutical field, but also sets higher expectations for the company's future development.
In the future, Doer Biologics will focus on innovative biopharmaceutical R&D, and take this as an opportunity to achieve more technological breakthroughs in the biopharmaceutical field, contributing to the high-quality development of the biopharmaceutical industry!
Zhejiang Doer Biologics Co., Ltd. ("Doer Biologics") is a clinical-stage biopharmaceutical company focused on discovering and developing multi-specific biotherapeutics based on multi-domain structures to address unmet medical needs in the fields of metabolic diseases and cancer.
Doer Biologics has developed a variety of proprietary technology platforms, including xLONGylation®, MultipleBody®, AccuBody®, and SMART-VHHBody.
For more information about Doer Biologics, please visit www.doerbio.com.